Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
1991-9-4
pubmed:abstractText
Oxathiin carboxanilide (OC), NSC 615985, a compound originally synthesized as a potential fungicide, was demonstrated to be highly active in preventing human immunodeficiency virus (HIV)-induced cell killing and in inhibiting HIV reproduction. Virus-infected CD4+ lymphocytes were completely protected by 0.5 microM OC, whereas no toxicity was observed at concentrations below 50 microM OC. Production of infectious virus, viral p24 antigen, and virion reverse transcriptase were reduced by OC at concentrations that prevented viral cell killing. A variety of CD4+ T-cell lines were protected by OC from HIV cytopathicity, and OC inhibited two distinct strains of HIV-1. However, HIV-2 infections were unaffected by OC. OC had no direct effect on virions of HIV or on the enzymatic activities of HIV reverse transcriptase or HIV protease. Time-limited treatments of cells with OC before, during, or after exposure of cells to virus failed to protect cells from the eventual cytopathic effects of HIV, and OC failed to inhibit the production of virus from cells in which infection was established or from chronically infected cells. We conclude that the highly active OC has a reversible effect on some early stage of HIV-1 reproduction and cytopathicity. Pilot in vivo experiments showed that circulating concentrations of OC exceeding 1 microM could be achieved and sustained in hamsters for at least a week with no remarkable toxicological sequelae. OC represents a new class of anti-HIV agents that are promising candidates for drug development.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-14323993, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-1689015, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-1694680, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-2405486, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-2441266, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-2467383, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-2469387, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-2471199, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-2495366, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-2647085, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-2666638, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-2891981, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-3120727, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-3299089, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-3299090, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-4170280, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-6189183, http://linkedlifedata.com/resource/pubmed/commentcorrection/1713689-6200936
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
88
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6740-4
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction.
pubmed:affiliation
Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S.